Compare
Farxiga vs. Wegovy

Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.

• Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
• Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
• Lowering the risk of hospitalization and death due to heart problems in people with heart failure
• Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)

• Vaginal yeast infection in females (7-8%)
• Nose and throat infection (6-7%)
• Urinary tract infection (UTI, 4-6%)

• Ketoacidosis
• Low fluids in the body (leading to low blood pressure or dehydration)
• Genital and urinary tract infections
• Low blood sugar (hypoglycemia) when used with other diabetes medications

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It comes in prefilled pens you use to inject the medication under the skin once a week. Wegovy (semaglutide) also comes as tablets that are swallowed once a day. This medication is approved for weight loss in some people. It can help lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. The pens are also approved for certain adults with a liver problem called metabolic dysfunction-associated steatohepatitis (MASH). The medication works best when taken with a lower-calorie diet and regular exercise. Side effects include nausea, diarrhea, and stomach pain.

Injectable pens:

• Weight loss and long-term weight management in:

  • People ages 12 years and older who are considered obese
  • Adults considered overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, high cholesterol)

• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring, but not cirrhosis

Tablets:

• Weight loss and long-term weight management in adults who are considered obese or overweight with at least one weight-related condition
• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Stomach pain (20%)
• Headache (14%)
• Tiredness (11%)

• Possible risk for thyroid cancer
• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems
• Low blood sugar
• Kidney damage
• Allergic reactions
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Faster heart rate
• Lung problems during general anesthesia or deep sedation